Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.–(BUSINESS WIRE)–Aug. 14, 2023–
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted non-qualified stock option awards to purchase an aggregate of 739,750 shares of its Class A common stock to 8 new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan (the “2023 Inducement Plan”). The stock options were granted as inducements material to the new employees becoming employees of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $3.24 per share, which is equal to the closing price of Quantum-Si’s Class A common stock on The Nasdaq Global Market on July 17, 2023, the date of grant of the options. Each option will vest over a four-year period, with 25% of the shares vesting on the last day of the calendar quarter that is 12 months after the employee’s start date and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Quantum-Si on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantumsi.supremeclients.com.

Investor Contact
Juan Avendano
[email protected]

Media Contact
Michael Sullivan
[email protected]

Source: Quantum-Si Incorporated